Damien Kee

List of Publications by Year
in descending order

18 papers	2,922 citations	759233 12 h-index	940533 16 g-index
18 all docs	18 docs citations	18 times ranked	4495 citing authors

#	Article	IF	Citations
1	Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K. Cancer Cell, 2010, 18, 683-695.	16.8	1,139
2	RASMutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors. New England Journal of Medicine, 2012, 366, 207-215.	27.0	978
3	Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b study. Lancet Oncology, The, 2014, 15, 954-965.	10.7	225
4	Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers. JAMA Oncology, 2020, 6, 1405.	7.1	157
5	Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare Cancers. Clinical Cancer Research, 2020, 26, 4454-4459.	7.0	110
6	Rheumatic immune-related adverse events secondary to antiâ€“programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series. European Journal of Cancer, 2018, 105, 88-102.	2.8	53
7	Ipilimumab in pretreated patients with unresectable or metastatic cutaneous, uveal and mucosal melanoma. Medical Journal of Australia, 2014, 201, 49-53.	1.7	52
8	Current and emerging strategies for the management of imatinib-refractory advanced gastrointestinal stromal tumors. Therapeutic Advances in Medical Oncology, 2012, 4, 255-270.	3.2	42
9	Acquired RAD51C Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma. Cancer Research, 2021, 81, 4709-4722.	0.9	42
10	Evaluation of TMB as a predictive biomarker in patients with solid cancers treated with anti-PD-1/CTLA-4 combination immunotherapy. Cancer Cell, 2021, 39, 592-593.	16.8	41
11	Combination immunotherapy with ipilimumab and nivolumab in patients with advanced adrenocortical carcinoma: a subgroup analysis of CA209-538. OncoImmunology, 2021, 10, 1908771.	4.6	21
12	RAF1 rearrangements are common in pancreatic acinar cell carcinomas. Modern Pathology, 2020, 33, 1811-1821.	5.5	19
13	Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES). , 2021, 9, e002995.		18
14	EWSR1-BEND2 fusion defines an epigenetically distinct subtype of astroblastoma. Acta Neuropathologica, 2022, 143, 109-113.	7.7	11
15	Combination immunotherapy with nivolumab and ipilimumab in patients with rare gynecological malignancies: results of the CA209-538 clinical trial. , 2021, 9, e003156.		6
16	Clinical and radiological evolution of cerebral amyloid angiopathy-related inflammation in the context of anti-PD-1 immunotherapy. Melanoma Research, 2020, 30, 608-612.	1.2	5
17	Potentially actionable FGFR2 high-level amplification in thymic sebaceous carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 476, 323-327.	2.8	2
18	CART-WHEEL.org: An Ethically Approved Online Database for Patient-Entered Data to Facilitate Rare Cancer Research. JCO Clinical Cancer Informatics, 2020, 4, 136-146.	2.1	1